GSK – INTERIM EFFICACY AND SAFETY DATA FOR BLENREP AS A FIRST LINE TREATMENT ARE EXPECTED IN EARLY 2028

GSK – INTERIM EFFICACY AND SAFETY DATA FOR BLENREP AS A FIRST LINE TREATMENT ARE EXPECTED IN EARLY 2028

(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)

The post GSK – INTERIM EFFICACY AND SAFETY DATA FOR BLENREP AS A FIRST LINE TREATMENT ARE EXPECTED IN EARLY 2028 appeared first on The Sunday Guardian.